On this page
- The placebo-controlled trial
- More cells did not mean more benefit
- The meta-analysis, and its limits
- Lupus nephritis is not all lupus
- Where this sits against standard treatment
- How it is given
- Why lupus is unusually hard to study
- Risks specific to lupus
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
Systemic lupus erythematosus is the autoimmune condition most often named in stem cell marketing, and it is one of the few with a placebo-controlled trial behind it. Stem cell therapy for lupus is therefore unusual here: the evidence exists, it is randomised, and it is not the evidence the marketing implies.
The placebo-controlled trial
Allogeneic umbilical cord-derived cells were tested against placebo in lupus nephritis — A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis.
Double-blind and placebo-controlled is the design that matters. Lupus fluctuates naturally, patients are on background immunosuppression, and disease activity scores respond to attention — all reasons an uncontrolled study will show improvement whatever is given.
Ask any clinic quoting lupus evidence whether they are quoting this trial, and what its result was. The answer is informative in both directions.
More cells did not mean more benefit
A separate study compared two transplantations against one — Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus.
The title states the finding. Doubling the treatment did not improve the outcome.
This matters commercially, because packages of repeated infusions are priced per infusion. In the one lupus study that tested the question, the second one added cost and not benefit.
The meta-analysis, and its limits
A meta-analysis of cell therapy in lupus has been published — Efficacy of mesenchymal stem cells on systemic lupus erythematosus: a meta-analysis.
Meta-analyses pool studies, and pooling small uncontrolled studies with controlled ones produces a number that looks precise and rests on unequal foundations.
A more recent double-blind randomised trial has examined cord-cell secretome rather than the cells themselves — Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial — which is a different product again.
Lupus nephritis is not all lupus
The controlled evidence is in kidney involvement. Lupus nephritis is a defined, biopsy-confirmed, measurable problem with hard endpoints — proteinuria, kidney function, renal response.
Lupus without kidney involvement presents as joint pain, rashes, fatigue and a long list of variable symptoms. Those are harder to measure, more responsive to expectation, and have not been the subject of the controlled trials.
Fatigue in particular is the symptom most often cited in testimonials and least reliably captured in trials. It is also the symptom most likely to improve temporarily for reasons unrelated to treatment.
Where this sits against standard treatment
Lupus nephritis has established treatment with strong evidence, and the last decade has added new drugs with large randomised trials behind them.
Trials of cell therapy have generally been in patients refractory to that treatment — people who have already tried and failed the established options.
If you have not yet been through standard treatment with a rheumatologist, that is where the evidence is, and swapping it for an infusion is not supported by anything published.
How it is given
Intravenous infusion of allogeneic cells, most often from donated umbilical cord tissue, dosed per kilogram of body weight.
Cells are cleared rapidly and the proposed effect is a signalling window rather than engraftment — mesenchymal stem cell therapy covers what is known about distribution and persistence.
Background immunosuppression is normally continued through trials, not stopped. Any proposal that involves stopping your medication should be checked with your rheumatologist first.
Why lupus is unusually hard to study
Lupus relapses and remits on its own. A patient recruited during a flare is, statistically, likely to improve over the following months whatever is done, simply because flares subside. That is regression to the mean, and it produces impressive uncontrolled results in every lupus treatment ever tried.
The disease also affects different organs in different people. Two patients with the same diagnosis may have kidney disease and joint pain respectively, and a treatment helping one tells you nothing about the other. Trials handle this with composite activity scores, which are useful but blunt.
Almost everyone in a lupus trial is also taking other drugs — steroids, hydroxychloroquine, immunosuppressants — which are adjusted during the study. Separating the effect of an infusion from a steroid taper running alongside it requires a control group taking the same drugs, which is precisely what the placebo-controlled trial provided and what an uncontrolled clinic series cannot.
These are not reasons to dismiss the research. They are the reasons the randomised trial matters far more here than the volume of positive case reports.
Risks specific to lupus
Infection risk in a patient already immunosuppressed, which is the principal safety concern in this group.
Infusion reactions and transient fever are the commonly reported short-term events.
Disease flare after any change in treatment, including a change made to accommodate a new one. Adverse events covers the broader safety picture.
Pregnancy planning deserves a separate conversation. Lupus interacts with pregnancy in both directions, several standard drugs are unsafe in pregnancy and others are not, and adding an unlicensed treatment into that picture complicates an already complicated decision.
Questions worth asking
- Do I have kidney involvement, and has it been confirmed on biopsy?
- Have I completed established treatment for this, and what did a rheumatologist advise?
- Which lupus trial is this protocol based on, and what did it find?
- How many infusions, and what is the basis for that number given the dosing study?
The autoimmune overview sets out the wider picture, and the limits of current evidence covers what is not yet known.
Frequently asked questions
Is there real evidence in lupus?
Yes — a randomised double-blind placebo-controlled trial in lupus nephritis, which is more than almost any other condition here has. Ask what it found.
Should I have more than one infusion?
One study compared two transplantations with one and found no additional benefit from the second.
Does it help lupus without kidney involvement?
The controlled evidence is in lupus nephritis. Joint pain, rash and fatigue have not been the subject of those trials.
Can I stop my current medication?
Trials generally continued background immunosuppression rather than stopping it. That decision belongs with your rheumatologist.
Is it a cure?
No published trial has reported anything resembling that, and nothing on this site should be read as suggesting it.
What about secretome or exosome products?
A double-blind randomised trial has tested cord-cell secretome in lupus. It is a different product from the cells and should not be sold as the same thing.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.